Oral PDE5 inhibitors are the treatment of choice for ED. The three currently available PDE5 inhibitors share many major similarities in that they are effective, well tolerated and cost-effective. However, healthcare providers may wish to examine the differences in these agents when choosing the most suitable treatment for their patient. Matching the right treatment to each patient is vital in order to ensure that the patient and his partner can return to normal sex life.
CLICK HERE for subscription information about this journal. Printer- Friendly Email ThisAcknowledgements
Dr Wright has received financial support for the development of this manuscript from Eli Lilly and he would like to thank Andrea Cole from Gardiner-Caldwell Communications for her assistance in drafting the manuscript.Reprint Address
Correspondence: Patrick J. Wright, MBChB, MRCGP, General Practitioner and Specialist Practitioner in Male Sexual Dysfunction, Belmont Surgery, Broomside Lane, Belmont, Durham DH1 2QW, UK Tel.: + 44 0191 3862517 Fax: + 44 0191 3860592 Email: firstname.lastname@example.org
Int J Clin Pract. 2006;60(8):967-975. ©2006 Blackwell Publishing
This is a part of article Phosphodiesterase Type 5 (PDE5) Inhibitors in Erectile Dysfunction Taken from "Buy Levitra Viagra Online" Information Blog